SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-18-006522
Filing Date
2018-08-07
Accepted
2018-08-07 06:57:25
Documents
57
Period of Report
2018-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q syrs-20180630x10q.htm 10-Q 1481860
2 EX-31.1 syrs-20180630ex31117d4b4.htm EX-31.1 10259
3 EX-31.2 syrs-20180630ex312f56e5d.htm EX-31.2 10783
4 EX-32.1 syrs-20180630ex3214a5147.htm EX-32.1 7443
5 EX-32.2 syrs-20180630ex3224def75.htm EX-32.2 7437
  Complete submission text file 0001558370-18-006522.txt   5547238

Data Files

Seq Description Document Type Size
6 EX-101.INS syrs-20180630.xml EX-101.INS 1177567
7 EX-101.SCH syrs-20180630.xsd EX-101.SCH 40340
8 EX-101.CAL syrs-20180630_cal.xml EX-101.CAL 39257
9 EX-101.DEF syrs-20180630_def.xml EX-101.DEF 144613
10 EX-101.LAB syrs-20180630_lab.xml EX-101.LAB 369333
11 EX-101.PRE syrs-20180630_pre.xml EX-101.PRE 271330
Mailing Address 620 MEMORIAL DRIVE SUITE 300 CAMBRIDGE MA 02139
Business Address 620 MEMORIAL DRIVE SUITE 300 CAMBRIDGE MA 02139 617-744-1340
Syros Pharmaceuticals, Inc. (Filer) CIK: 0001556263 (see all company filings)

IRS No.: 453772460 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37813 | Film No.: 18996239
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences